Second-line afatinib significantly improves PFS in metastatic head and neck cancer

Bookmark and Share
Published: 27 Sep 2014
Views: 2751
Dr Jean-Pascal Machiels - Cliniques Universitaires Saint-Luc, Brussels, Belgium

At a press conference at ESMO 2014, Dr Machiels presents the results of his study which looked at the impact of afatinib versus methotrexate upon progression-free survival in patients with head and neck cancer.

Read the news story or watch the interview for more.